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Copyright © 2014 Valderilio Feijó Azevedo et al.This is an open access article distributed under theCreative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the originalwork is properly cited.
Relapsing polychondritis (RP) is an autoimmune disease characterized by recurrent episodes of inflammation and progressive
destruction of cartilaginous tissues, especially of the ears, nose, joints, and tracheobronchial tree. Its etiology is not well understood,
but some studies have linked its pathophysiology with autoimmune disease and autoantibody production. We described a case of
a 46-year-old male patient with ankylosing spondylitis who developed RP after the use of etanercept. Few similar cases have been
described in the literature. However, they show a possible association between the use of biological inhibitors of tumor necrosis
factor (anti-TNF𝛼), which potentially produces autoantibodies, and the development of RP.The treatment was based on data in the
literature and included the cessation of biological therapy and the addition of corticosteroids with substantial improvement.
1. Introduction
Relapsing polychondritis (RP) is a rare disease characterized
by recurring inflammation and destruction of cartilaginous
tissues such as the ears, nose, and larynx [1]. Few cases of
RP have appeared in the literature, and its pathophysiology
is not completely explained, but it is believed that it is
an autoimmune event [2]. It is known that around 30%
of patients with RP have other concomitant autoimmune
diseases, such as systemic lupus erythematosus or Sjögren’s
syndrome [3]. However, the association with ankylosing
spondylitis (AS) is uncommon [4, 5]. Currently, the therapy
with antitumor necrosis factor alpha (anti-TNF𝛼) is the best
alternative to the use of nonsteroidal anti-inflammatories
(NSAIDs) for the treatment of AS with predominantly axial
symptoms [6, 7]. Although rare, the formation of antibodies
and autoantibodies and the development of immune diseases
are associated with the use of anti-TNF𝛼 agents. There is
evidence that a small percentage of patients using anti-TNF𝛼
therapy will develop autoimmune diseases including vasculi-
tis, lupus-like syndrome, and cutaneous psoriatic lesions [8].
Case studies have also revealed a connection between the use
of anti-TNF𝛼 and the development of RP [9].
2. Case Report
J. D. is a male, 46 years of age, with clinical presentation of
inflammatory low back pain for 10 years, along with stiffness
of the lumbar spine in the morning. He began treatment in
our ambulatory spondyloarthritis clinic around 1 year earlier,
when the definitive diagnosis of AS was made according to
the modified New York criteria [10]. The patient was HLA
B27-positive and presented with bilateral sacroiliitis in stage
III confirmed by conventional radiography.
Despite the continuous use of Ibuprofen 60mg 8/8 h,
sulfasalazine 1 g 12/12 h, prednisone 5mg/day, and codeine
30mg 8/8 h for 6 months, the patient’s condition worsened,
with the inflammatory lower back pain intensifying, synovitis
in the right ankle, and unilateral calcaneal enthesitis. At
that time, the patient presented a BASDAI score of 6.7 and
a CRP of 6.7mg/dL. According to recommendations from
the ASAS group and the consensus of the Brazilian Society
of Rheumatology [11, 12], anti-TNF𝛼 therapy was selected
for treatment. Consequently, there was a slow withdrawal
of prednisone and an onset of therapy with etanercept at
the dose of 50mg subcutaneous once a week. NSAIDs and
sulfasalazine were continued.
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Two months after starting etanercept, the patient devel-
oped erythema and nasal pain, accompanied by swelling
of the left and right ears which did not affect the earlobes
(Figure 1). The CRP had fallen to 3.2mg/dL. ANA and
cryoglobulin tests were negative. Other causes of chondritis,
such as trauma and infection, were discarded because of the
absence of suggestive history. Besides, infectious chondritis
usually involves also the earlobe. The presumptive clinical
diagnosis of RP was established. The use of etanercept was
temporarily suspended and therapy with prednisone 10mg/
day was introduced.
Only three months after the use of anti-TNF𝛼 was
suspended did the patient report improvement in the pain,
nasal erythema, and auricular swelling. However, there was
a significant worsening of the lower back inflammation and
the calcaneal enthesitis. The patient’s BASDAI score rose to
7.6, with no significant increase in the RP.
Upon physical examination, there were no nasal alter-
ations. However, mild hyperemia was present in the ears,
which was not very painful. We decided to continue corti-
costeroids therapy and reintroduce anti-TNF𝛼 therapy with
etanercept due to the worsening of the axial symptoms and
enthesitis.
After five months of treatment, the patient showed com-
plete improvement of the inflammatory lower back pain, of
the arthritis in the ankles, and of the calcaneal enthesitis.
The ear and nose symptoms had disappeared. The patient
continued to take prednisone 10mg/day, nimesulide 100mg
12/12 h, and etanercept 50mg SC once a week.
3. Discussion
The use of anti-TNF𝛼 drugs has been one of the best
alternatives for the treatment of rheumatic diseases which
resist treatment with nonsteroidal anti-inflammatories [8].
Etanercept has demonstrated great efficacy in treating the
axial symptoms of spondyloarthritis as well as enthesitis and
synovitis [7]. Although it is generally well tolerated, studies
of etanercept have shown significant adverse effects such as
headaches, diarrhea, airway infections, reactivation of latent
infections, and, in some cases, the induction of psoriasis
and uveitis [7, 9]. Furthermore, patients using anti-TNF𝛼
may develop autoantibodies such as antinuclear antibodies
(ANAs) and anti-double stranded DNA antibodies (anti-
DNAds) [8].
Although the etiology of RP is not yet completely under-
stood, it is presumed that it has an autoimmune origin due to
its frequent association with autoimmune diseases and with
the presence of the human leukocyte antigen (HLA)DR4 [13].
It is also known that anti-collagen antibodies, mainly Type
II, can be seen during an acute RP episode; these antibodies
are probably the result of the liberation of inflammatory
cytokines such as TNF𝛼, IL1, and IL6 [14, 15].Themain clini-
cal manifestation of RP is uni- or bilateral auricular chondri-
tis, as seen in our patient.The ear frequently becomes swollen,
erythematic, and painful, but the earlobe is not affected
[16]. Other important symptoms that may occur in RP are
polyarthritis; chondritis of the nasal cartilage, the larynx, and
the tracheal cartilage; inflammation of the ocular structures;
Figure 1
and involvement of the vestibulocochlear system [2, 3].
However, these symptoms were not reported in this case.
Currently, the use of biological medications has been
discussed as part of the treatment for RP, especially in
cases when treatment with corticosteroids fails [2, 17, 18],
and the use of these molecules has expanded into the
treatment of other autoimmune comorbidities [19]. However,
two cases of RP during TNF-blocker therapy were reported
in Spain in 2011 [20]. Both patients were men with AS,
HLAB27 positive, with 45 and 49 years of age, respectively.
The first case was characterized by complaining of bilateral
pain, erythema, and swelling of the auricle, ocular symp-
toms, cough, and chest pain after two years of biologi-
cal therapy with etanercept 25mg twice weekly. RP was
diagnosed based on clinical manifestations; etanercept was
stopped and treatment with prednisone 5mg/day was started.
After three months, the treatment with etanercept was rein-
troduced with no recurrence of RP.The second patient devel-
oped bilateral auricular erythema with ocular hyperemia
and tearing in both eyes after four years of using infliximab
at a dose of 5mg/kg every 8 weeks. After the diagnosis
of RP, anti-TNF treatment was stopped and prednisone
1mg/kgwas started.Thepatient condition resolved slowly but
favorably.The patient remained asymptomatic, but the switch
to adalimumab 40mg every twoweekswas necessary because
of the recurrence of the axial symptoms.
In the present case report, the hypothesis is that RP
was a paradoxical event resulting from the use of anti-
TNF𝛼, possibly related to the development of autoantibodies
which triggered this autoimmune condition. Similar to our
patient, none of the patients described in the literature had
presented symptoms of RP before the institution of therapy
with biologicals. Although 30% of patients with RP have
some associated diseases, including vasculitis, diseases of the
conjunctive tissues, or autoimmune diseases [21], association
with AS is rare [20]. Only three cases associating the two
comorbidities without the concomitant use of biologicals
have been reported. Pazirandeh et al. described two cases of
AS in patients with RP [4], and Bahiri et al. reported a case
in a 28-year-old patient who was diagnosed with AS after 5
years of RP [5]. Consequently, the initial suspicion was that
RP resulted from the use of etanercept and not a clinical
condition associated with AS. According to the few pieces of
data in the literature, the response is to interrupt treatment
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with the biologicals and to begin corticosteroids therapy [22].
With this clinical response, substantial improvement in the
diagnosis of chondritis was achieved. Up to the time of this
writing, the patient did not develop symptoms compatible
with RP, even after reintroducing etanercept therapy. Despite
maintaining low-dose corticosteroids therapy, the develop-
ment of RP and its relation to inhibiting TNF𝛼 are not com-
pletely understood.
4. Conclusion
The introduction of anti-TNF𝛼 drugs into the treatment of
RP, ankylosing spondylitis, and other autoimmune diseases
has revolutionized the management of patients with active
diseases that resist conventional therapy. Nevertheless, the
use of these drugs has been associated with the development
of immunogenicity and also autoimmunity.The development
of autoimmune diseases during treatment with biological
drugs is rare butmust be recognized promptly to allow appro-
priate treatment. In the case reported here, the RP diagnosis
was eminently clinical and permitted quick and appropriate
management of the patient. Although the patient did not
develop recurring episodes of polychondritis, other causes
of chondritis were discarded. Furthermore, the fact that the
auricular symptoms went into remission after the suspension
of anti-TNF𝛼 and the introduction of corticosteroids therapy
supports the diagnosis of RP induced by the use of etanercept.
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